This inventor holds 1 USPTO granted patent. Top assignees: Shanghai Genbase Biotech Co., Ltd., The Fourth Military Medical University Xi'an. Active years: 2022.
Company Filing History:
1 out of 1 
1 out of 1 Years Active: 2022
Title: The Innovations of Kaichun Wu
Introduction
Kaichun Wu is a notable inventor based in Shaanxi, China. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for cancer detection and therapy. His work has the potential to impact the diagnosis and treatment of tumors, showcasing the importance of innovation in medical science.
Latest Patents
Kaichun Wu holds a patent for a "Single-chain antibody specifically binding MG7, highly glycosylated CEA and use thereof in detection and therapy." This invention provides a glycosylated CEA-specific single-chain antibody and a chimeric antigen receptor (CAR) targeting glycosylated CEA. These innovations can be utilized in the manufacture of agents or medicaments for the diagnosis or treatment of tumors that overexpress glycosylated CEA.
Career Highlights
Throughout his career, Kaichun Wu has worked with esteemed institutions such as the Fourth Military Medical University in Xi'an and Shanghai Genbase Biotech Co., Ltd. His experience in these organizations has allowed him to develop his expertise in biotechnology and contribute to significant advancements in the field.
Collaborations
Kaichun Wu has collaborated with notable professionals in his field, including Daiming Fan and Yongzhan Nie. These partnerships have fostered an environment of innovation and have led to the development of groundbreaking technologies in cancer treatment.
Conclusion
Kaichun Wu's contributions to biotechnology and his innovative patent demonstrate the vital role of inventors in advancing medical science. His work not only enhances our understanding of cancer treatment but also paves the way for future innovations in the field.